AR026826A1 - Arilcetonas sustituidas - Google Patents

Arilcetonas sustituidas

Info

Publication number
AR026826A1
AR026826A1 ARP010100097A ARP010100097A AR026826A1 AR 026826 A1 AR026826 A1 AR 026826A1 AR P010100097 A ARP010100097 A AR P010100097A AR P010100097 A ARP010100097 A AR P010100097A AR 026826 A1 AR026826 A1 AR 026826A1
Authority
AR
Argentina
Prior art keywords
thiocarbamoyl
alkylsulfinyl
alkylsulfonyl
carbamoyl
alkylthio
Prior art date
Application number
ARP010100097A
Other languages
English (en)
Original Assignee
Bayer Ag
Bayer Agrochem Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10039723A external-priority patent/DE10039723A1/de
Application filed by Bayer Ag, Bayer Agrochem Kk filed Critical Bayer Ag
Publication of AR026826A1 publication Critical patent/AR026826A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Abstract

La invencion se refiere a nuevas arilcetonas sustituidas de la formula general (1) en la que m significa los numeros 0, 1 o 2, A significa alcanodiilo(alquileno), R1 significa uno de los agrupamientos del numero 2 al 5 donde: m, R5, R6, R7, R8. R9, R 10, R11, R12, R13 tienen uno de los significados indicadosen la descripcion, R2 significa hidrogeno, nitro, ciano, carboxi, carbamoilo, tiocarbamoilo, halogeno, o significa alquilo, alcoxi, alquiltio, alquilsulfinilo,alquilsulfonilo, alquilamino, dia lqilamino o dialquilaminosulfonilo sustituidos resepectivamente en caso dado, R3 significa nitro, ciano, carboxi, carbamoilo,tiocarbamoilo, hallogeno o significa alquilo, alcoxi, alquiltio, alquilsulfinilo, alquilsulfonilo, alquilamino, dialquilamino o dialquilaminosulfonilosustituidos respectivamente en caso dado, y R4 significa un agrupamiento heterocíclico con 4 hasta 12 miembros, saturado o insaturado, monocíclico o bicíclicosustituido en caso dado, así como a procedimientos para su obtencio n, a productos intermedios y al empleo de estos compuestos como herbicidas.
ARP010100097A 1996-08-27 2001-01-10 Arilcetonas sustituidas AR026826A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2465996P 1996-08-27 1996-08-27
DE10001588 2000-01-17
DE10039723A DE10039723A1 (de) 2000-01-17 2000-08-14 Substituierte Arylketone

Publications (1)

Publication Number Publication Date
AR026826A1 true AR026826A1 (es) 2003-02-26

Family

ID=21821740

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970103851A AR009321A1 (es) 1996-08-27 1997-08-25 Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen y compuestos intermediarios.
ARP010100097A AR026826A1 (es) 1996-08-27 2001-01-10 Arilcetonas sustituidas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP970103851A AR009321A1 (es) 1996-08-27 1997-08-25 Compuestos derivados de 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen y compuestos intermediarios.

Country Status (41)

Country Link
EP (1) EP0925298B1 (es)
JP (1) JP2000502722A (es)
KR (1) KR100457759B1 (es)
CN (2) CN1138774C (es)
AP (1) AP1164A (es)
AR (2) AR009321A1 (es)
AT (1) ATE264327T1 (es)
AU (1) AU726771C (es)
BG (1) BG64316B1 (es)
BR (1) BR9711262A (es)
CA (1) CA2263913C (es)
CO (1) CO4930259A1 (es)
CZ (1) CZ67799A3 (es)
DE (1) DE69728676T2 (es)
DK (1) DK0925298T3 (es)
DZ (1) DZ2299A1 (es)
EA (1) EA002607B1 (es)
ES (1) ES2216157T3 (es)
GT (1) GT199700093A (es)
HK (1) HK1019597A1 (es)
HR (1) HRP970452A2 (es)
ID (1) ID18189A (es)
IL (1) IL128049A (es)
IS (1) IS4970A (es)
MY (1) MY132671A (es)
NO (1) NO316273B1 (es)
NZ (1) NZ333728A (es)
OA (1) OA10980A (es)
PA (1) PA8435001A1 (es)
PE (1) PE108698A1 (es)
PL (1) PL331988A1 (es)
PT (1) PT925298E (es)
SI (1) SI0925298T1 (es)
SK (1) SK22599A3 (es)
TN (1) TNSN97144A1 (es)
TR (1) TR199900408T2 (es)
TW (1) TW477787B (es)
UA (1) UA66345C2 (es)
WO (1) WO1998008846A1 (es)
YU (1) YU35697A (es)
ZA (1) ZA977652B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
NZ333727A (en) 1996-08-06 2000-09-29 Pfizer Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic arylsulfonylamino hydroxamic acid derivatives
CA2281525A1 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
ES2207834T3 (es) * 1997-04-22 2004-06-01 Janssen Pharmaceutica N.V. Quino- y quinazolinas antagonistas del crf.
NL1010018C2 (nl) * 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CN1217945C (zh) 1998-11-12 2005-09-07 纽罗克里恩生物科学有限公司 Crf受体拮抗剂以及与其有关的方法
ATE240958T1 (de) 1998-11-12 2003-06-15 Neurocrine Biosciences Inc Crf rezeptor-antagonisten und darauf bezogene methoden
JP2002536445A (ja) * 1999-02-12 2002-10-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー オレキシン受容体アンタゴニストとしてのフェニル尿素およびフェニルチオ尿素誘導体
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CZ20021086A3 (cs) 1999-09-30 2002-10-16 Neurogen Corporation Alkylendiaminem substituované heterocykly
ES2258479T3 (es) 1999-10-01 2006-09-01 JOHNSON & JOHNSON CONSUMER COMPANIES, INC. Tecnica que permite calmar a las personas con la ayuda de composiciones de tratamientos personales.
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
DE60026186T2 (de) 2000-01-26 2006-11-16 Em Microelectronic-Marin S.A., Marin Verfahren zur Prüfung einer integrierten Schaltung mit vertraulichen Software- oder Hardware-elementen
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6500839B2 (en) 2000-05-18 2002-12-31 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
HU229471B1 (en) 2000-10-23 2014-01-28 Smithkline Beecham Corp 2,4,8-trisubstituted-8h-pyrido[2,3d]pyrimidine-7-one compounds, for the treatment of diseases mediated by csbp/p38 kinase
CA2446514A1 (en) * 2001-04-30 2002-11-07 Glaxo Group Limited Fused pyrimidines as antagonists of the corticotropin releasing factor (crf)
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
GB2411478A (en) 2002-01-29 2005-08-31 Johnson & Johnson Consumer Method of measuring the stress or relaxation level of a mammal
CA2482022A1 (en) 2002-04-19 2003-10-30 Smithkline Beecham Corporation Novel compounds
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
EP1599468B1 (en) 2003-01-14 2007-10-03 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
NZ544200A (en) 2003-07-14 2009-07-31 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
JP2007501822A (ja) 2003-08-12 2007-02-01 エフ．ホフマン−ラ　ロシュ　アーゲー コルチコトロピン放出性因子（ｃｒｆ）アンタゴニストとしてのスピロ置換テトラヒドロキナゾリン
WO2005014557A1 (en) 2003-08-12 2005-02-17 F.Hoffmann-La Roche Ag Tetrahydroquinazoline derivatives as cfr antagonists
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP2006232849A (ja) * 2003-08-13 2006-09-07 Japan Tobacco Inc 含窒素縮合環化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
CN1917882A (zh) * 2004-02-13 2007-02-21 辉瑞产品公司 非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
CA2590294A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
KR20080002865A (ko) 2005-03-25 2008-01-04 글락소 그룹 리미티드 피리도[２,３-ｄ]피리미딘-７-온 및３,４-디히드로피리미도[４,５-ｄ]피리미딘-２(１ｈ)-온유도체의 제조 방법
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
JP4318744B2 (ja) 2005-03-31 2009-08-26 ファイザー・プロダクツ・インク シクロペンタピリジンおよびテトラヒドロキノリン誘導体
WO2007076035A2 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
RU2441869C2 (ru) 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
EP2078016B1 (en) 2006-10-19 2012-02-01 Signal Pharmaceuticals LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
WO2008133753A2 (en) 2006-12-20 2008-11-06 Abbott Laboratories Anti-viral compounds
BRPI0811745B1 (pt) * 2007-05-17 2019-06-04 Helperby Therapeutics Limited Compostos de 4-(pirrolidin-1-il)quinolina, uso e processo para a preparação dos mesmos, formulação farmacêutica --
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
ES2596243T3 (es) * 2012-08-24 2017-01-05 F. Hoffmann-La Roche Ag Nuevos derivados bicíclicos de piridina
EP3096756A1 (en) 2014-01-21 2016-11-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3636283A1 (en) 2015-06-04 2020-04-15 Pfizer Inc Solid dosage forms of palbociclib
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
KR102009756B1 (ko) * 2017-01-06 2019-08-12 고려대학교 세종산학협력단 신규한 퀴놀리논 유도체 및 이를 유효성분으로 포함하는 천식 또는 아토피 등의 알러지성 질환의 예방 또는 치료용 약학 조성물
CN115160221A (zh) * 2022-07-26 2022-10-11 上海歆贻医药科技有限公司 德立替尼晶型化合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
DK0765327T3 (da) * 1994-06-16 1999-11-29 Pfizer Pyrazolo- og pyrrolopyridiner
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
AU716993B2 (en) * 1995-05-12 2000-03-16 Neurogen Corporation Novel deazapurine derivatives; a new class of CRF1 specific ligands
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
DE69628804T2 (de) * 1995-12-08 2003-12-18 Pfizer Substitutierte heterozyclische Derivate als CRF Antagonisten

Also Published As

Publication number Publication date
DZ2299A1 (fr) 2002-12-25
CN1367169A (zh) 2002-09-04
CN1191236C (zh) 2005-03-02
EA199900166A1 (ru) 1999-08-26
GT199700093A (es) 1999-02-04
PE108698A1 (es) 1999-01-23
UA66345C2 (en) 2004-05-17
CO4930259A1 (es) 2000-06-27
JP2000502722A (ja) 2000-03-07
NO990892L (no) 1999-02-25
CZ67799A3 (cs) 1999-11-17
AP1164A (en) 2003-06-30
BG103192A (en) 1999-09-30
EP0925298A1 (en) 1999-06-30
ZA977652B (en) 1999-02-26
OA10980A (en) 2001-11-02
YU35697A (en) 1999-11-22
MY132671A (en) 2007-10-31
BR9711262A (pt) 1999-08-17
HRP970452A2 (en) 1998-08-31
AP9701076A0 (en) 1997-10-31
PL331988A1 (en) 1999-08-16
AR009321A1 (es) 2000-04-12
CA2263913C (en) 2004-06-29
BG64316B1 (bg) 2004-09-30
EP0925298B1 (en) 2004-04-14
TW477787B (en) 2002-03-01
NO990892D0 (no) 1999-02-25
DK0925298T3 (da) 2004-08-09
AU726771B2 (en) 2000-11-23
TNSN97144A1 (fr) 2005-03-15
SK22599A3 (en) 2000-07-11
CN1138774C (zh) 2004-02-18
IL128049A0 (en) 1999-11-30
AU726771C (en) 2004-11-11
DE69728676D1 (de) 2004-05-19
PT925298E (pt) 2004-07-30
ES2216157T3 (es) 2004-10-16
PA8435001A1 (es) 2002-07-30
IL128049A (en) 2004-12-15
HK1019597A1 (en) 2000-02-18
ATE264327T1 (de) 2004-04-15
EA002607B1 (ru) 2002-06-27
NO316273B1 (no) 2004-01-05
WO1998008846A1 (en) 1998-03-05
NZ333728A (en) 2000-11-24
KR20000035898A (ko) 2000-06-26
KR100457759B1 (ko) 2004-11-18
DE69728676T2 (de) 2004-09-30
TR199900408T2 (xx) 1999-05-21
SI0925298T1 (en) 2004-08-31
AU3355797A (en) 1998-03-19
CA2263913A1 (en) 1998-03-05
IS4970A (is) 1999-02-05
CN1228091A (zh) 1999-09-08
ID18189A (id) 1998-03-12

Similar Documents

Publication Publication Date Title
AR026826A1 (es) Arilcetonas sustituidas
AR006273A1 (es) Compuestos heterociclicos nitrogenados de anillos de 5 miembros como nuevos inhibidores de la resorcion osea y antagonistas de receptores de vitronectina,procedimiento para su preparacion, utilizacion de dichos compuestos para la preparacion de un medicamento, y preparado farmaceutico.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
ECSP034884A (es) Ligandos del receptor de 5-ht y sus usos
AR007961A1 (es) Derivados de cicloalquilo como inhibidores de la resorcion osea y antagonistas de receptores de vitronectina, procedimiento para su preparacion y preparado farmaceutico.
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
ES2045041T3 (es) Triazolinonas sustituidas.
ES2094380T3 (es) Nuevos pirazolilpirazoles sustituidos, procedimientos para su preparacion, asi como compuestos intermedios, y su uso como herbicidas.
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
ES2153106T3 (es) Aminofeniluracilos substituidos como herbicidas e insecticidas.
AR007770A1 (es) Nuevos diamino pirazoles, su sintesis, composiciones de tintura de fibras queratinicas que los contienen, procedimientos de tintura de fibrasqueratinicas.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
AR028743A1 (es) DERIVADOS DE N-TRIAZOLILMETIL-PIPERAZINA CON ACCIoN ANTAGONISTA DE RECEPTORES DE NEUROQUININA
ES2164765T3 (es) Heterociclilbenzonitrilos.
IS4367A (is) CCK eða gastrín temprandi 5-heterósýklísk-1,5-bensódíazepín
AR028947A1 (es) Compuestos novedosos
ES2160801T3 (es) Sulfonilaminocarboniltriazolinonas con halogeno alq(en)iltio-substituyentes, herbicidas y fungicidas.
ES2105939B1 (es) Nuevos pirazoles con actividad antagonista de la angiotensina ii.
BR0107624A (pt) Arilcetonas substituìdas
ES2179857T3 (es) Derivados de quinoleina sustituidos, procedimiento para su preparacion y su utilizacion.
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
SE9604582D0 (sv) Novel compounds
DE69900297T2 (de) Akarizid und insektizid wirksame, substituierte Pyrimidine und Verfahren zu ihrer Herstellung
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
ES2169480T3 (es) Procedimiento mejorado para la preparacion de compuestos asimetricos de 4,6-bis(ariloxi)pirimidina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure